DOCSLIB.ORG

NUAK1 Has Tumor Suppressive Activity in Epithelial Ovarian Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NUAK1 Has Tumor Suppressive Activity in Epithelial Ovarian Cancer Western University Scholarship@Western Electronic Thesis and Dissertation Repository 6-21-2017 12:00 AM NUAK1 Has Tumor Suppressive Activity in Epithelial Ovarian Cancer Parima Saxena The University of Western Ontario Supervisor Dr. Trevor Shepherd The University of Western Ontario Graduate Program in Anatomy and Cell Biology A thesis submitted in partial fulfillment of the equirr ements for the degree in Master of Science © Parima Saxena 2017 Follow this and additional works at: https://ir.lib.uwo.ca/etd Part of the Cancer Biology Commons, and the Cell Biology Commons Recommended Citation Saxena, Parima, "NUAK1 Has Tumor Suppressive Activity in Epithelial Ovarian Cancer" (2017). Electronic Thesis and Dissertation Repository. 4598. https://ir.lib.uwo.ca/etd/4598 This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of Scholarship@Western. For more information, please contact [email protected]. Abstract NUAK1, a downstream substrate of the stress metabolism regulator Liver kinase B1 (LKB1), has been implicated as an oncogene and tumor suppressor, with distinct roles in cell cycle, senescence and cell adhesion. Epithelial ovarian cancer (EOC) spheroids remain dormant during intraperitoneal metastasis with reduced proliferation and metabolism to survive metabolically harsh conditions, possibly implicating a role of NUAK1 in EOC spheroid biology. I hypothesize that NUAK1 is regulated by LKB1 to promote dormancy in EOC. I demonstrate that NUAK1 expression and phosphorylation is regulated by LKB1 in EOC cell lines. NUAK1 is largely under-expressed in many established and new ascites-derived EOC cell lines; in fact, further NUAK1 knockdown increases spheroid cell viability, size, and reattachment capability. Pharmacologic NUAK1/2 inhibition increased EOC cell growth and clonogenicity. Collectively, my data supports NUAK1 as having tumour suppressive activity downstream of LKB1 in EOC. Keywords Liver Kinase B1, AMPK-related kinase, NUAK1, spheroid, tumor suppressor, epithelial ovarian cancer, metastasis Co-Authorship Statement OVCAR8 STK11KO cells were established by Dr. Trevor Shepherd using CRISPR-Cas9 technology to lack LKB1 expression. iOvCa series, ascites-derived cell lines, were established by Dr. Gabriel DiMattia. siARK screen was performed by Yudith Ramos-Valdes. qPCR for ARK mRNA levels was conducted by Elizabeth Kobylecky. Tritiated thymidine incorporation assay was performed in collaboration with Piru Perampalam and Dr. Fred Dick i Acknowledgments I would like to acknowledge my supervisor, Dr. Trevor Shepherd, for allowing me to take on this interesting and engaging project and for his support throughout the course of my project. I would also like to thank my committee members for all of their insightful guidance which they have provided me, which has been critical for driving this project forward. I would also like to thank Dr. Gabriel DiMattia for all of his contributions towards my project, valuable insight into my work, and for generously allowing me to use the repository of ascites-derived cell lines. Furthermore, I would like to thank my past and present lab mates, Yudith, Adrian, Olga, Jessica and Samah, for not only helping me learn scientific techniques but for also providing an excellent work environment. ii Table of Contents Abstract ................................................................................................................................. Co-Authorship Statement..................................................................................................... i Acknowledgments............................................................................................................... ii Table of Contents ............................................................................................................... iii List of Tables ..................................................................................................................... vi List of Figures ................................................................................................................... vii List of Abbreviations ......................................................................................................... ix Chapter 1 ............................................................................................................................. 1 1 Introduction .................................................................................................................... 1 1.1 Epidemiology, Clinical Presentation and Treatment of Epithelial Ovarian Cancer 1 1.2 Origin and Subtypes of EOC .................................................................................. 3 1.3 EOC Metastasis and Experimental Model Systems................................................ 6 1.4 LKB1-AMPK in EOC Metastasis ........................................................................... 9 1.5 AMPK-Related Kinases and Their Potential Importance in EOC Metastasis ...... 12 1.6 NUAK1 Regulation and Function ........................................................................ 14 1.7 Research Goal, Hypothesis and Experimental Objectives .................................... 17 Chapter 2 ........................................................................................................................... 18 2 Materials and Methods ................................................................................................. 18 2.1 Cell Culture ........................................................................................................... 18 2.2 Western Blot ......................................................................................................... 20 2.3 Phostag™ Western Blot ........................................................................................ 22 2.4 siRNA-mediated knockdown ................................................................................ 22 2.5 Reattachment Assays ............................................................................................ 23 2.6 Clonogenic Assays ................................................................................................ 23 iii 2.7 CellTiter-Glo® Viability Assay ............................................................................ 23 2.8 CyQUANT Viability Assay .................................................................................. 24 2.9 Trypan Blue Exclusion Viability Assay ............................................................... 24 2.10 IC50 Determination .............................................................................................. 25 2.11 Incucyte ZOOM Growth Curves .......................................................................... 26 2.12 Quantitative Real-time PCR ................................................................................. 26 2.13 Tritiated Thymidine Incorporation Assay ............................................................. 29 2.14 Spheroid size determination .................................................................................. 29 2.15 Graphing and Statistical Analysis ......................................................................... 29 Chapter 3 ........................................................................................................................... 30 3 Results .......................................................................................................................... 30 3.1 NUAK1 has limited profile in EOC...................................................................... 30 3.2 NUAK1 expression decreases in spheroid culture................................................ 33 3.3 NUAK1 is regulated by LKB1 ............................................................................. 33 3.4 NUAK1 knockdown increases EOC spheroid cell viability ................................. 36 3.5 NUAK1 and NUAK2 are unable to functionally compensate for each other ....... 38 3.6 NUAK1 inhibition increases EOC cell growth and clonogenicity ....................... 44 3.7 Specific NUAK1 inhibition increases EOC cell growth ....................................... 45 3.8 NUAK1 inhibition is insufficient to induce platinum sensitivity ......................... 51 3.9 NUAK1 inhibition does not affect thymidine incorporation ................................ 55 Chapter 4 ........................................................................................................................... 59 4 Discussion .................................................................................................................... 59 4.1 Summary of findings............................................................................................. 59 4.2 Potential growth suppressive of NUAK1 in EOC ................................................ 60 4.3 Therapeutic implications of results ....................................................................... 63 4.4 NUAK1 and LKB1 ............................................................................................... 63 iv 4.5 Limitations of current study .................................................................................. 64 4.6 Future Work .......................................................................................................... 65 4.7 Overall Conclusion ..............................................................................................
Load more

Recommended publications
  • Two Locus Inheritance of Non-Syndromic Midline Craniosynostosis Via Rare SMAD6 and 4 Common BMP2 Alleles 5 6 Andrew T
    1 2 3 Two locus inheritance of non-syndromic midline craniosynostosis via rare SMAD6 and 4 common BMP2 alleles 5 6 Andrew T. Timberlake1-3, Jungmin Choi1,2, Samir Zaidi1,2, Qiongshi Lu4, Carol Nelson- 7 Williams1,2, Eric D. Brooks3, Kaya Bilguvar1,5, Irina Tikhonova5, Shrikant Mane1,5, Jenny F. 8 Yang3, Rajendra Sawh-Martinez3, Sarah Persing3, Elizabeth G. Zellner3, Erin Loring1,2,5, Carolyn 9 Chuang3, Amy Galm6, Peter W. Hashim3, Derek M. Steinbacher3, Michael L. DiLuna7, Charles 10 C. Duncan7, Kevin A. Pelphrey8, Hongyu Zhao4, John A. Persing3, Richard P. Lifton1,2,5,9 11 12 1Department of Genetics, Yale University School of Medicine, New Haven, CT, USA 13 2Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT, USA 14 3Section of Plastic and Reconstructive Surgery, Department of Surgery, Yale University School of Medicine, New Haven, CT, USA 15 4Department of Biostatistics, Yale University School of Medicine, New Haven, CT, USA 16 5Yale Center for Genome Analysis, New Haven, CT, USA 17 6Craniosynostosis and Positional Plagiocephaly Support, New York, NY, USA 18 7Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, USA 19 8Child Study Center, Yale University School of Medicine, New Haven, CT, USA 20 9The Rockefeller University, New York, NY, USA 21 22 ABSTRACT 23 Premature fusion of the cranial sutures (craniosynostosis), affecting 1 in 2,000 24 newborns, is treated surgically in infancy to prevent adverse neurologic outcomes. To 25 identify mutations contributing to common non-syndromic midline (sagittal and metopic) 26 craniosynostosis, we performed exome sequencing of 132 parent-offspring trios and 59 27 additional probands.
    [Show full text]
  • Essential Genes and Their Role in Autism Spectrum Disorder
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2017 Essential Genes And Their Role In Autism Spectrum Disorder Xiao Ji University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Bioinformatics Commons, and the Genetics Commons Recommended Citation Ji, Xiao, "Essential Genes And Their Role In Autism Spectrum Disorder" (2017). Publicly Accessible Penn Dissertations. 2369. https://repository.upenn.edu/edissertations/2369 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2369 For more information, please contact [email protected]. Essential Genes And Their Role In Autism Spectrum Disorder Abstract Essential genes (EGs) play central roles in fundamental cellular processes and are required for the survival of an organism. EGs are enriched for human disease genes and are under strong purifying selection. This intolerance to deleterious mutations, commonly observed haploinsufficiency and the importance of EGs in pre- and postnatal development suggests a possible cumulative effect of deleterious variants in EGs on complex neurodevelopmental disorders. Autism spectrum disorder (ASD) is a heterogeneous, highly heritable neurodevelopmental syndrome characterized by impaired social interaction, communication and repetitive behavior. More and more genetic evidence points to a polygenic model of ASD and it is estimated that hundreds of genes contribute to ASD. The central question addressed in this dissertation is whether genes with a strong effect on survival and fitness (i.e. EGs) play a specific oler in ASD risk. I compiled a comprehensive catalog of 3,915 mammalian EGs by combining human orthologs of lethal genes in knockout mice and genes responsible for cell-based essentiality.
    [Show full text]
  • Strategies and Opportunities for Small Molecule Drug Discovery to Target Neurodegenerative Diseases Andrea I
    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.01.020206; this version posted April 2, 2020. The copyright holder has placed this preprint (which was not certified by peer review) in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose without crediting the original authors. Defining the Neural Kinome: Strategies and Opportunities for Small Molecule Drug Discovery to Target Neurodegenerative Diseases Andrea I. Krahn, Carrow Wells, David H. Drewry, Lenore K. Beitel, Thomas M. Durcan, Alison D. Axtman* ABSTRACT: Kinases are highly tractable drug targets that have reached unparalleled success in fields such as cancer but whose potential has not yet been realized in neuroscience. There are currently 55 approved small molecule kinase-targeting drugs, 48 of which have an anti-cancer indication. The intrinsic complexity linked to central nervous system (CNS) drug development and a lack of validated targets has hindered progress in developing kinase inhibitors for CNS disorders when compared to other therapeutic areas such as oncology. Identification and/or characterization of new kinases as potential drug targets for neurodegenerative diseases will create opportunities for development of CNS drugs in the future. The track record of kinase inhibitors in other disease indications supports the idea that with the best targets identified small molecule kinase modulators will become impactful therapeutics for neurodegenerative diseases. KEYWORDS: kinase, neurodegeneration,
    [Show full text]
  • Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer
    Epigenetic mechanisms are involved in the oncogenic properties of ZNF518B in colorectal cancer Francisco Gimeno-Valiente, Ángela L. Riffo-Campos, Luis Torres, Noelia Tarazona, Valentina Gambardella, Andrés Cervantes, Gerardo López-Rodas, Luis Franco and Josefa Castillo SUPPLEMENTARY METHODS 1. Selection of genomic sequences for ChIP analysis To select the sequences for ChIP analysis in the five putative target genes, namely, PADI3, ZDHHC2, RGS4, EFNA5 and KAT2B, the genomic region corresponding to the gene was downloaded from Ensembl. Then, zoom was applied to see in detail the promoter, enhancers and regulatory sequences. The details for HCT116 cells were then recovered and the target sequences for factor binding examined. Obviously, there are not data for ZNF518B, but special attention was paid to the target sequences of other zinc-finger containing factors. Finally, the regions that may putatively bind ZNF518B were selected and primers defining amplicons spanning such sequences were searched out. Supplementary Figure S3 gives the location of the amplicons used in each gene. 2. Obtaining the raw data and generating the BAM files for in silico analysis of the effects of EHMT2 and EZH2 silencing The data of siEZH2 (SRR6384524), siG9a (SRR6384526) and siNon-target (SRR6384521) in HCT116 cell line, were downloaded from SRA (Bioproject PRJNA422822, https://www.ncbi. nlm.nih.gov/bioproject/), using SRA-tolkit (https://ncbi.github.io/sra-tools/). All data correspond to RNAseq single end. doBasics = TRUE doAll = FALSE $ fastq-dump -I --split-files SRR6384524 Data quality was checked using the software fastqc (https://www.bioinformatics.babraham. ac.uk /projects/fastqc/). The first low quality removing nucleotides were removed using FASTX- Toolkit (http://hannonlab.cshl.edu/fastxtoolkit/).
    [Show full text]
  • Supplemental Tables
    Supplemental Tables 1 (Up in 1 (Up in Log2 AD80) / 2 Log2 1 (Up in Log2 AD80) / 2 Fold (Low in Fold AD80) / 2 Fold Gene (Low in AD30) change Gene AD30) change Gene (Low in AD30) change G6PC 1 8.262795 SYT8 1 3.826244 SPATA9 1 3.10268 ADH1B 1 7.508264 ADH4 1 3.800391 SPTSSB 1 3.093815 RNU1-70P 1 6.596403 WNT8B 1 3.799741 CYP26A1 1 3.093672 CYP7A1 1 6.56167 TNFSF10 1 3.795007 ACR 1 3.092358 ADH1A 1 6.358759 HMGCS2 1 3.791218 DUOX2 1 3.090622 SLC2A2 1 6.05681 GNAT1 1 3.737262 SPTLC3 1 3.086353 TNFRSF14- AS1 1 6.055208 CFHR4 1 3.732386 FER1L5 1 3.081569 IGFALS 1 5.825777 BSND 1 3.718276 RASA4CP 1 3.080765 LINC00957 1 5.727226 TSPOAP1 1 3.709555 DOC2GP 1 3.057021 TTBK1 1 5.724558 SLC22A7 1 3.698323 VAT1L 1 3.051293 CYP3A43 1 5.674953 AOC4P 1 3.68655 FMO3 1 3.031314 HNF4A- UGT1A9 1 5.643359 AS1 1 3.679788 SFRP5 1 3.016623 APOL3 1 5.448612 FHAD1 1 3.665007 RFX6 1 3.015833 - VCAM1 1 5.442271 ADAMTS10 1 3.61034 SLC5A8 2 3.015901 BFSP2 1 5.396028 NUDT13 1 3.562774 LFNG 2 -3.01667 C22orf31 1 5.349548 FYTTD1P1 1 3.544783 CXCR4 2 -3.0544 FOXN1 1 5.19046 CHAD 1 3.534052 GPR3 2 -3.099 - A2MP1 1 5.186347 IRF5 1 3.517716 PA2G4P6 2 3.103813 - UROC1 1 5.056845 GSTA7P 1 3.504839 PRDM8 2 3.140796 - XAF1 1 5.053767 CXCL10 1 3.486513 DGKG 2 3.261431 - ADAMTS14 1 5.049252 SERPINA2 1 3.481204 BCAN 2 3.389266 - UGT1A8 1 5.048674 WDR93 1 3.475799 MMP10 2 3.411248 - TTLL11-IT1 1 4.965854 MAP6 1 3.465613 MYBPC3 2 3.492397 HRC 1 4.853162 MOV10L1 1 3.457172 MUC12 2 -3.55192 - MOGAT2 1 4.797347 HP 1 3.456436 FGF18 2 3.551928 - SEPT7P9 1 4.735573 MT1B 1 3.43852 MYO1G
    [Show full text]
  • Inhibition of ERK 1/2 Kinases Prevents Tendon Matrix Breakdown Ulrich Blache1,2,3, Stefania L
    www.nature.com/scientificreports OPEN Inhibition of ERK 1/2 kinases prevents tendon matrix breakdown Ulrich Blache1,2,3, Stefania L. Wunderli1,2,3, Amro A. Hussien1,2, Tino Stauber1,2, Gabriel Flückiger1,2, Maja Bollhalder1,2, Barbara Niederöst1,2, Sandro F. Fucentese1 & Jess G. Snedeker1,2* Tendon extracellular matrix (ECM) mechanical unloading results in tissue degradation and breakdown, with niche-dependent cellular stress directing proteolytic degradation of tendon. Here, we show that the extracellular-signal regulated kinase (ERK) pathway is central in tendon degradation of load-deprived tissue explants. We show that ERK 1/2 are highly phosphorylated in mechanically unloaded tendon fascicles in a vascular niche-dependent manner. Pharmacological inhibition of ERK 1/2 abolishes the induction of ECM catabolic gene expression (MMPs) and fully prevents loss of mechanical properties. Moreover, ERK 1/2 inhibition in unloaded tendon fascicles suppresses features of pathological tissue remodeling such as collagen type 3 matrix switch and the induction of the pro-fbrotic cytokine interleukin 11. This work demonstrates ERK signaling as a central checkpoint to trigger tendon matrix degradation and remodeling using load-deprived tissue explants. Tendon is a musculoskeletal tissue that transmits muscle force to bone. To accomplish its biomechanical function, tendon tissues adopt a specialized extracellular matrix (ECM) structure1. Te load-bearing tendon compart- ment consists of highly aligned collagen-rich fascicles that are interspersed with tendon stromal cells. Tendon is a mechanosensitive tissue whereby physiological mechanical loading is vital for maintaining tendon archi- tecture and homeostasis2. Mechanical unloading of the tissue, for instance following tendon rupture or more localized micro trauma, leads to proteolytic breakdown of the tissue with severe deterioration of both structural and mechanical properties3–5.
    [Show full text]
  • Control of AMPK-Related Kinases by USP9X and Atypical Lys29/Lys33
    Control of AMPK-related kinases by USP9X and atypical Lys29/Lys33-linked polyubiquitin chains Abdallah K Al-Hakim, Anna Zagorska, Louise Chapman, Maria Deak, Mark Peggie, Dario R Alessi To cite this version: Abdallah K Al-Hakim, Anna Zagorska, Louise Chapman, Maria Deak, Mark Peggie, et al.. Control of AMPK-related kinases by USP9X and atypical Lys29/Lys33-linked polyubiquitin chains. Biochemical Journal, Portland Press, 2008, 411 (2), pp.249-260. 10.1042/BJ20080067. hal-00478950 HAL Id: hal-00478950 https://hal.archives-ouvertes.fr/hal-00478950 Submitted on 30 Apr 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Biochemical Journal Immediate Publication. Published on 06 Feb 2008 as manuscript BJ20080067 Control of AMPK-related kinases by USP9X and atypical Lys29/Lys33-linked polyubiquitin chains. By Abdallah K. Al-Hakim1, Anna Zagorska1, Louise Chapman1, Maria Deak1, Mark Peggie1, and Dario R. Alessi1 MRC Protein Phosphorylation Unit, MSI/WTB complex, University of Dundee, Dow Street, Dundee DD1 5EH, Scotland. Correspondence to DRA ([email protected]) Tel +44 1382 344241 Fax +44 1382 223778 Running Title: USP9X deubiquitinates NUAK1 and MARK4 Key words: Ubiquitin specific protease, protein kinase, ubiquitination, deubiquitination, LKB1.
    [Show full text]
  • A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma
    Int. J. Mol. Sci. 2016, 17, 739; doi:10.3390/ijms17050739 S1 of S5 Supplemental Material: A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma Jun Lai, Zhan Zhou, Xiao-Jing Tang, Zhi-Bin Gao, Jie Zhou and Shu-Qing Chen Table S1. 725 targeted genes in GenCapTM oncocap_725 kit. ABI1 ABI3 ABL1 ABL2 ABLIM1 ACBD6 ACCS ACSL3 ACSL6 ACVR1B ADAM12 ADAM19 ADAM29 ADAMTS16 ADAMTS18 ADAMTS20 ADAMTSL3 AFF1 AFF3 AIM1 AKAP12 AKAP9 AKT1 AKT2 AKT3 ALK APC APC2 APOL1 ARF1 ARHGAP26 ARHGEF12 ARID1A ARNT ARRB2 ASF1A ASPSCR1 ASXL1 ATF1 ATIC ATM ATP10B ATP13A3 BAG2 BAP1 BCL10 BCL11A BCL11B BCL2 BCL2L1 BCL3 BCL6 BCL7A BCL9 BCR BHLHE40 BIN1 BIRC3 BLM BMI1 BMPR1A BNIP3L BRAF BRCA1 BRCA2 BRD3 BRD4 BRD7 BRIP1 BTG1 BUB1 BUB1B C15orf55 C18orf32 C2orf40 CANT1 CAPN1 CARD10 CARD11 CARD8 CARS CASC5 CASP1 CASP8 CBFA2T3 CBFB CBL CBLB CBLC CBX8 CCDC6 CCL2 CCL26 CCNA2 CCNB1 CCNB1IP1 CCND1 CCND2 CCND3 CCNDBP1 CD27 CD3EAP CD74 CDC25C CDC42EP1 CDC6 CDC73 CDH1 CDH10 CDH11 CDK1 CDK2 CDK4 CDK5 CDK6 CDKN1A CDKN1B CDKN1C CDKN2A CDKN2AIP CDKN2B CDKN2C CDKN2D CDX2 CEBPA CEP110 CHCHD7 CHEK1 CHEK2 CHIC2 CHN1 CIC CIITA CIRBP CITED2 CLDN1 CLP1 CLTC CLTCL1 CNBP COL1A1 COMMD2 COMMD3 COMMD4 COMMD5 COMMD6 COMMD8 COX6C CRAF CREB1 CREB3L2 CREBBP CREG1 CRTC1 CRTC3 CSF1R CTNNA1 CTNNA2 CTNNB1 CTSF CTSW CXCL1 CXCR7 CYB561 CYLD DAP3 DARC DCLRE1B DDB2 DDIT3 DDX10 DDX5 DDX6 DEK DICER1 DLEC1 DMTF1 DNMT3A DUSP3 DUSP4 DUSP6 DYRK1A E2F1 E2F3 EDF1 EFEMP1 EGFR EIF4A2 ELF4 ELK4 ELL ELN EML4 ENDOG EP300 EPHA3 EPHA4 EPHA7 EPHB6 EPS15 Int.
    [Show full text]
  • Kinome Expression Profiling to Target New Therapeutic Avenues in Multiple Myeloma
    Plasma Cell DIsorders SUPPLEMENTARY APPENDIX Kinome expression profiling to target new therapeutic avenues in multiple myeloma Hugues de Boussac, 1 Angélique Bruyer, 1 Michel Jourdan, 1 Anke Maes, 2 Nicolas Robert, 3 Claire Gourzones, 1 Laure Vincent, 4 Anja Seckinger, 5,6 Guillaume Cartron, 4,7,8 Dirk Hose, 5,6 Elke De Bruyne, 2 Alboukadel Kassambara, 1 Philippe Pasero 1 and Jérôme Moreaux 1,3,8 1IGH, CNRS, Université de Montpellier, Montpellier, France; 2Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium; 3CHU Montpellier, Laboratory for Monitoring Innovative Therapies, Department of Biologi - cal Hematology, Montpellier, France; 4CHU Montpellier, Department of Clinical Hematology, Montpellier, France; 5Medizinische Klinik und Poliklinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany; 6Nationales Centrum für Tumorerkrankungen, Heidelberg , Ger - many; 7Université de Montpellier, UMR CNRS 5235, Montpellier, France and 8 Université de Montpellier, UFR de Médecine, Montpel - lier, France ©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2018.208306 Received: October 5, 2018. Accepted: July 5, 2019. Pre-published: July 9, 2019. Correspondence: JEROME MOREAUX - [email protected] Supplementary experiment procedures Kinome Index A list of 661 genes of kinases or kinases related have been extracted from literature9, and challenged in the HM cohort for OS prognostic values The prognostic value of each of the genes was computed using maximally selected rank test from R package MaxStat. After Benjamini Hochberg multiple testing correction a list of 104 significant prognostic genes has been extracted. This second list has then been challenged for similar prognosis value in the UAMS-TT2 validation cohort.
    [Show full text]
  • Colorectal Tumors Require NUAK1 for Protection from Oxidative Stress
    Published OnlineFirst March 2, 2018; DOI: 10.1158/2159-8290.CD-17-0533 RESEARCH ARTICLE Colorectal Tumors Require NUAK1 for Protection from Oxidative Stress Jennifer Port1, Nathiya Muthalagu2, Meera Raja1, Fatih Ceteci2, Tiziana Monteverde1, Björn Kruspig1, Ann Hedley2, Gabriela Kalna2, Sergio Lilla2, Lisa Neilson2, Martina Brucoli1, Katarina Gyuraszova1, Jacqueline Tait-Mulder1, Mokdad Mezna3, Silvija Svambaryte1, Amy Bryson1, David Sumpton2, Allan McVie1, Colin Nixon2, Martin Drysdale3, Hiroyasu Esumi4, Graeme I. Murray5, Owen J. Sansom1,2, Sara R. Zanivan1,2, and Daniel J. Murphy1,2 Downloaded from cancerdiscovery.aacrjournals.org on September 26, 2021. © 2018 American Association for Cancer Research. Published OnlineFirst March 2, 2018; DOI: 10.1158/2159-8290.CD-17-0533 ABSTRACT Exploiting oxidative stress has recently emerged as a plausible strategy for treat- ment of human cancer, and antioxidant defenses are implicated in resistance to chemotherapy and radiotherapy. Targeted suppression of antioxidant defenses could thus broadly improve therapeutic outcomes. Here, we identify the AMPK-related kinase NUAK1 as a key component of the antioxidant stress response pathway and reveal a specific requirement for this role of NUAK1 in colorectal cancer. We show that NUAK1 is activated by oxidative stress and that this activation is required to facilitate nuclear import of the antioxidant master regulator NRF2: Activation of NUAK1 coordinates PP1β inhibition with AKT activation in order to suppress GSK3β-dependent inhibition of NRF2 nuclear import. Deletion of NUAK1 suppresses formation of colorectal tumors, whereas acute depletion of NUAK1 induces regression of preexisting autochthonous tumors. Importantly, elevated expression of NUAK1 in human colorectal cancer is associated with more aggressive disease and reduced overall survival.
    [Show full text]
  • Dual Targeting of NUAK1 and ULK1 Using the Multitargeted Inhibitor
    Chen et al. Cell Death and Disease (2020) 11:712 https://doi.org/10.1038/s41419-020-02885-0 Cell Death & Disease ARTICLE Open Access Dual targeting of NUAK1 and ULK1 using the multitargeted inhibitor MRT68921 exerts potent antitumor activities Yiran Chen1, Xiaoling Xie 1, Chunsheng Wang1,YuxingHu1, Honghao Zhang1,LengheZhang1,SanfangTu1, Yanjie He1 and Yuhua Li 1,2 Abstract Utilizing oxidative stress has recently been regarded as a potential strategy for tumor therapy. The NUAK family SNF1- like kinase 1 (NUAK1) is a critical component of the antioxidant defense system and is necessary for the survival of tumors. Therefore, NUAK1 is considered an attractive therapeutic target in cancer. However, antioxidant therapy induced elevated ROS levels to activate the Unc-51-like kinase 1 (ULK1) pathway to promote protective autophagy and ULK1-dependent mitophagy. Thus, the combined inhibition of NUAK1 and ULK1 showed a strong synergistic effect in different tumor types. Herein, the potential antitumor activities of a dual NUAK1/ULK1 inhibitor MRT68921 were evaluated in both tumor cell lines and animal models. MRT68921 significantly kills tumor cells by breaking the balance of oxidative stress signals. These results highlight the potential of MRT68921 as an effective agent for tumor therapy. Introduction 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; NUAK1 (also known as ARK5) is one of 12 kinases from Tumor cells possess an infinite drive to proliferate, the AMPK subfamily and is critical for maintaining exposing them to more severe metabolic stress than metabolic homeostasis by regulating the mitochondrial normal cells1. Increased metabolic stress promotes the respiratory chain complex and the metabolism of gluta- production of elevated reactive oxygen species (ROS), mine5.
    [Show full text]
  • Identification of Functional Genetic Variants in Inflammatory Bowel Disease by Genome and Transcriptome Sequencing
    Identification of Functional Genetic Variants in Inflammatory Bowel Disease by Genome and Transcriptome Sequencing Dissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Christian-Albrechts-Universität zu Kiel vorgelegt von Matthias Barann August, 2012 Kiel, Deutschland 1 2 Referent/in: Prof. Dr. Philip Rosenstiel Korreferent/in: Prof. Dr. Dr. h.c. Thomas Bosch Tag der mündlichen Prüfung: 31.10.2012 Zum Druck genehmigt: 31.10.2012 gez. Prof. Dr. Wolfgang J. Duschl, Dekan 3 Parts of this dissertation are contained in the following two manuscripts. Rosenstiel R, Barann M, Klostermeier UC, Sheth V, Ellinghaus D, Rausch T, Korbel J, Nothnagel M, Krawczak M, Gilissen C, Veltman J, Forster M, Stade B, McLaughlin S, Lee CC, Fritscher-Ravens A, Franke A, Schreiber S. Whole Genome Sequence of a Crohn disease trio Barann M, Klostermeier UC, Esser D, Ammerpohl O, Siebert R, Sudbrak R, Lehrach H, Schreiber S, Rosenstiel R. Janus – Investigating the two faces of transcription 4 Contents 1. Introduction ............................................................................................................................. 7 1.1. Pathogenesis of inflammatory bowel diseases ...................................................................................... 8 1.2. Physical barrier function of the gut ......................................................................................................... 11 1.3. Pathogen recognition ..................................................................................................................................
    [Show full text]